Figure 1. A) Infliximab-induced psoriasiform dermatitis of the scalp. B, C) Infliximab-induced
plantar pustular psoriasis. D) Severe erosions, inflammation, and alopecia under …

Dear Editor, Etanercept is a dimeric fusion protein which blocks the interaction of both tumor
necrosis factor (TNF)-a and TNF-b with their corresponding receptors. 1 It shows high …

DEAR EDITOR, The incremental benefits of obtaining high levels of skin clearance for
patients with psoriasis have been established across several patient-reported outcomes …

DISCUSSION Few articles have been published concerning psoriasis among twins (1).
Psoriasis in concordant, monozygotic twin pairs tends to be similar with respect to age of …

Biological therapies used in psoriasis treatment pose a risk of reactivation of hepatitis B virus
(HBV) infection. This risk occurs not only in patients with HB surface antigen (HBsAg)(+) but …

Letters S117 infliximab therapy. Although the skin and the PA showed a dramatic
improvement, infliximab had to be discontinued because of severe thrombocytopenia. We …

For patients with moderate-to-severe psoriasis, current guidelines recommend systemic
treatment to achieve adequate disease control. 1 Although more than 90 percent of …

Psoriasis is a chronic, inflammatory and potentially disfiguring disease. In one third of cases
the first manifestations appear before the age of 16 years [1]. The need for suitable treatment …

Psoriasis, an immune-mediated inflammatory skin disease, presents a significant health and
19 economic impact on patients and society1, 2. For the treatment of moderate to severe …

Over the past few years the development of registries for patients with psoriasis has
flourished. So far, the majority of published results from biological registries in psoriasis …